INTRODUCTION

Verruca vulgaris is caused by human papillomavirus (HPV) infection of the epidermis. The most common sites of infection are the hands, feet and face [1]. Verruca in the external auditory canal (EAC) has rarely been reported [2-5]. A previous case report introduced surgical excision as a treatment for verruca in the EAC. We present a case of verruca vulgaris in both EACs that was successfully treated with an intralesional bleomycin injection. A 32-year-old male patient presented with ear fullness and palpable lumps in both EACs. Both of his canals were filled with multiple pinkish, papillomatous masses. Verruca vulgaris was confirmed by skin biopsy. An otolaryngologist referred this patient and recommended surgical excision. However, we performed intralesional bleomycin injections for treatment. Twice intralesional bleomycin injections at one-month intervals had excellent results without recurrence, ulceration or scar formation. This result indicates that bleomycin injections may prove to be an effective first-line treatment of verruca in the EAC.

CASE REPORT

A 32-year-old male patient presented with ear fullness and palpable lumps in both EACs. The lumps were identified 18 months prior to the examination and the patient indicated that the lumps appeared to be getting larger. The patient had not undergone any specific treatment. Otoscopic examination revealed multiple pinkish, papillomatous masses that filled both of his EACs (Fig. 1A, B). The tympanic membrane and the surrounding tissue were intact. Verruca was confirmed by punch biopsy (Fig. 2). An otolaryngologist referred this patient and recommended surgical excision and skin grafting. However, we performed intralesional bleomycin injections for treatment. Twice intralesional bleomycin injections at one-month intervals had excellent results without recurrence, ulceration or scar formation. This result indicates that bleomycin injections may prove to be an effective first-line treatment of verruca in the EAC.

Bleomycin was diluted with 1% lidocaine to make a 1-U/mL bleomycin solution. A 1-mL syringe with a 30-gauge needle was used to directly inject the bleomycin solution until the verruca was completely blanched. The bleomycin solution was injected twice; 0.5 mL at the first injection and 0.2 mL at the second injection one month later.

One month after first injection, the verruca decreased to approximately one-third of the initial size (Fig. 1C, D). Two months after the second injections, the verruca was not observed and there was no scarring or necrosis (Fig. 1E, F). Eight months after the second injection, the patient confirmed that there was no recurrence.
DISCUSSION

Verruca vulgaris is caused by an HPV infection, and there are over 100 human papilloma DNA viruses that belong to the DNA papovaviridae family [1-5]. The most common sites of infection are the hands, feet and face [1]. Histopathological examination is used for a definitive diagnosis, and revealed characteristic features of hyperkeratosis, papillomatosis, parakeratosis, acanthosis, and koilocytosis [3-5].

Verruca in the EAC has rarely been reported. It is associated with low-risk HPV infections (types 6 and 11) that often result in a benign clinical course with no recurrence or malignant transformation [3-5]. The mode of HPV transmission to EAC is currently not known. EAC infections are thought to be associated with a history of repeated manipulation using the finger tips or ear picking tools. In addition, it has been suggested that the hair follicles may serve as possible reservoirs [2-5]. EAC verruca causes mechanical obstruction which can lead to pressure necrosis of the adjacent bone or conductive hearing impairments, although tympanic membrane involvement is seldom reported [2,4].

There are currently several methods to treat verruca, which include topical treatments, cryotherapy, immunotherapy, photodynamic therapy, laser therapy, curettage and cautery, radiation therapy, surgical excision and intralesional bleomycin injections [1-4,6]. A case report introduced surgical excision of verruca in the EAC as the preferred treatment because of difficulty to apply nonsurgical treatment such cryotherapy, photodynamic therapy or laser therapy [2]. However, the most common complication...
associated with surgical excision is the possibility of scarring and subsequent EAC stenosis [4].

Intralesional bleomycin injections have been used to treat verruca on the hands, forearm, feet and face [1,6-10]. Bleomycin was originally isolated from the fungus, *Streptomyces verticillus*, and is frequently used as an antitumor agent. Bleomycin blocks the cell cycle at G2, cleaves single-stranded and double-stranded DNA and degrades cellular RNAs; it also forms a complex with metal ions, which reduce oxygen to free radicals [7,8]. These free radicals cause DNA breaks that ultimately lead to cell death. Other possible underlying mechanisms are endothelial damage, which induce tumor necrosis factor, hemorrhage of subepidermis and intraepidermis, and the appearance of apoptotic cells [7,8,10,11]. Bleomycin is hydrophilic and does not easily cross cell membranes [7]. The cytotoxic effect and uptake of bleomycin is increased by mixing drug with local anesthetics because local anesthetics disrupt the cell membrane structure [12].

After bleomycin intralesional injection, verruca on the hands and feet has exhibited hemorrhagic black eschars which suggest adequate bleomycin infiltration. Eschar formation is thought to be caused by absolutely decreased blood flow, necrosis, and subsequent detachment of the lesion [7]. Eschar on the hands and feet typically separate after 2 to 3 weeks [8].

However, verruca on the face indicated that the verruca gradually shrank after injection, and disappeared without eschar formation [9]. We thought that the blood supply is decreased after injection but not completely interrupted because of rich and large dermal capillaries of the face. Incomplete blockage of blood flow may not cause hemorrhagic necrosis, eschar formation and consequential verruca detachment. Induction of endothelial and keratinocyte apoptosis by direct or indirect damage may be result in verruca shrinkage without necrosis or eschar. Verruca in the EAC disappeared without eschars after injections. Its clinical course was similar to one of verruca on the face.

In conclusion, we present a case of large and multiple verruca in both EACs that was successfully treated with twice intralesional bleomycin injections at one-month interval. There was no complication, such as ulceration, scar formation or recurrence. An intralesional bleomycin injection is simple, easy to apply without any difficulty and limitation, and had a high degree of patient satisfaction for treatment of verruca in the EAC. We propose that it may be an effective, first-line treatment of verruca in the EAC.

CONFLICT OF INTEREST

No potential conflict of interest relevant to this article was reported.

ACKNOWLEDGMENTS

This article was presented as a poster at the 2nd Research and Reconstructive Forums on Jun 1–3, 2012, in Korea.

REFERENCES

1. Androphy EJ, Kirnbauer R. Human papilloma virus infections. In: Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ, Wolff K, editors. Fitzpatrick’s dermatology in general medicine. 8th ed. New York: McGraw-Hill; 2012. p. 2421-33.
2. Kim J, Lee DH, Cho KJ, Lee SY. Huge verruca vulgaris (wart) of the external auditory canal. Otolaryngol Head Neck Surg. 2008 Dec; 139(6):865-6.
3. Wang S, Yee H, Wen HY, Wang BY. Papillomas of the external ear canal: report of ten cases in Chinese patients with HPV in situ hybridization. Head Neck Pathol. 2009 Sep;3(3):207-11.
4. Chang NC, Chien CY, Wu CC, Chai CY. Squamous papilloma in the external auditory canal: a common lesion in an uncommon site. World J Clin Cases. 2013 May;1(2):92-5.
5. Xia MY, Zhu WY, Lu JY, Lu Q, Chen L. Ultrastructure and human papillomavirus DNA in papillomatosis of external auditory canal. Int J Dermatol. 1996 May;35(5):337-9.
6. Sterling JC, Handfield-Jones S, Hudson PM; British Association of Dermatologists. Guidelines for the management of cutaneous warts. Br J Dermatol. 2001 Jan;144(1):4-11.
7. Saitta P, Krishnamurthy K, Brown LH. Bleomycin in dermatology: a review of intralesional applications. Dermatol Surg. 2008 Oct;34(10):1299-313.
8. Yamamoto T. Bleomycin and the skin. Br J Dermatol. 2006 Nov; 155(5):869-75.
9. Burn JS, Oh SJ. Intralesional Bleomycin injection for the treatment of Warts. J Korean Soc Aesthetic Plast Surg. 1997 Oct;3(1):81-7.
10. Templeton SF, Solomon AR, Swerlick RA. Intralesional bleomycin injections into normal human skin: a histopathologic and immunopathologic study. Arch Dermatol. 1994 May;130(5):577-83.
11. James MP, Collier PM, Aherne W, Hardcastle A, Lovegrove S. Histologic, pharmacologic, and immunocytochemical effects of injection of bleomycin into viral warts. J Am Acad Dermatol. 1993 Jun;28(6): 933-7.
12. Mizuno S, Ishida A. Selective enhancement of bleomycin cytotoxicity by local anesthetics. Biochem Biophys Res Commun. 1982 Mar; 105(2):425-31.